About Event

Targeted Protein Degradation continues to progress as a therapeutic with huge potential, and 2023 shaped up to be a landmark year for the degradation community. With the emergence of over 88 newly disclosed TPD drugs in the first half of 2022 and over 67 TPD drug updates and critical collaborations – this community continues to advance highly valuable degrader compounds closer to the clinic.

What You Missed:

favicon

Hear Keynote Presentations Outlining the Current Landscape and Late-Breaking Case-Studies from Degradation Leaders with presentations from Nurix, Proxygen & Amphista Therapeutics

favicon

Learn and Overcome the Challenges towards an Improved the Safety Profile of PROTACs and Progress Your Candidates into the Clinic with presentations from AstraZeneca & Bayer

favicon

Review the Next Generation Advances PROTAC, Molecular Glues and Combination Therapies Across Different Therapeutic Indications with presentations from Sibylla Biotech, Kymera & Mission Therapeutics

favicon

Consider How to Optimise Degrader Design via Enhanced Assay Selection and Development and Boost Degrader Translation with presentations from Technical University Darmstadt & AstraZeneca

favicon

Deep-Dive into the Progress within Computational Modelling of TPD toward an Improved Structural Prediction and Understanding of Selectivity with presentations from Celeris Therapeutics, Aelin Therapeutics & Nurix Therapeutics

Copy of TPD News Headlines (2)
EVENT GUIDE
REGISTER
PARTNER